Altre lingue Syngene International Limited

Azioni

SYNGENE

INE398R01022

Tempo differito NSE India S.E. Altri mercati azionari 10:44:17 11/07/2024			Variaz. 5gg	Var. 1 gen.
738,6 ^INR	-0,80%		+1,80%	+5,32%

26/04	SYNGENE INTERNATIONAL LIMITED : Jefferies & Co. ormai pessimista	ZM
25/04	Transcript : Syngene International Limited, Q4 2024 Earnings Call, Apr 25, 2024

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Syngene International Limited Proposes Final Dividend for the Financial Year Ended March 31, 2024	02/07
Syngene International Limited Receives an Intimation from the Superintendent of Central Tax, Bangalore South Commissionerate, Bangalore	20/06
Syngene International Limited Submits an Appeal to the National Faceless Appeal Centre, for Assessment Year 2022-23	28/04
Syngene International Limited Submits an Appeal to the Commissioner of Income-Tax-12, Bangalore, for Assessment Year 2017-18 and 2018-19	24/04
Syngene International Limited Recommends Final Dividend for the Financial Year 2024	24/04
Syngene International Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	24/04
Syngene International Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	24/04
Syngene International Limited Submits an Appeal to the Commissioner of Income-Tax-12, Bangalore, for Assessment Year 2013-14 and 2014-15	22/04
INDIA STOCKS-Financials drag Indian shares, hit by fading US rate cut hopes	12/04
Syngene Biologics Manufacturing Facility to Be Operational for U.S. and European Customers from Mid-Year	14/03
Bristol Myers CEO says India to have largest R&D presence outside US by 2025	27/02
Syngene International Posts Gains in Fiscal Q3 Consolidated Net Profit	26/01
Syngene International Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	25/01
Syngene International Limited Appoints Mr. Sibaji Biswas as Additional Director Designated as Executive Director, Effective on April 01, 2024	25/01
Syngene International Completes Acquisition of Stelis Biopharma's Biologics Plant	04/12
Syngene International Limited completed the acquisition of Unit 3 biologics manufacturing facility in Bangalore from Stelis Biopharma Private Limited for INR 6.2 billion.	01/12
FOCUS -Indian drug manufacturers benefit from Big Pharma interest beyond China	27/11
Syngene International COO Steps Down	31/10/23
Syngene International Limited Announces Resignation of Mahesh Bhalgat as Chief Operating Officer, Effective January 31, 2024	31/10/23
Syngene International Limited Announces Resignation of Carl Decicco as Non-Executive Director	25/10/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Syngene International Limited

Azioni

SYNGENE

INE398R01022

Altre lingue

Filtri